Stage I nonsmall cell lung carcinoma - Analysis of survival and implications for screening

被引:0
作者
Dominioni, L
Imperatori, A
Rovera, F
Ochetti, A
Torrigiotti, G
Paolucci, M
机构
[1] Azienda Osped Circolo Varese, Varese, Italy
[2] Univ Insubria, Ctr Thorac Surg, Varese, Italy
关键词
lung carcinoma; Stage I; early diagnosis; overdiagnosis; screening; survival; cure;
D O I
10.1002/1097-0142(20001201)89:11+<2334::AID-CNCR4>3.0.CO;2-I
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND, Skepticism about the radical curability of lung carcinoma, even when diagnosed in Stage I, has been long fostered by the epidemiologists' dogma against lung cancer screening, and by official recommendations not to screen for lung carcinoma. Follow-up of patients with asymptomatic screen-detected Stage I nonsmall cell lung carcinoma (NSCLC), however, shows that patients who underwent radical resection have long term survival rates, whereas patients nonsurgically treated or undergoing suboptimal operations have much poorer prognosis. The latter clinical outcome data strongly suggest the importance of detecting lung carcinoma when it is in Stage I and cast serious doubts on the recommendation not to screen for lung carcinoma. DATA. The scrutiny of the biology, epidemiology, and clinical features of Stage I NSCLC clarifies important aspects of the ongoing controversy concerning the value of screening for early diagnosis (Stage I) of lung carcinoma. The biologic characteristics of Stage I NSCLC (histologic types, doubling time, metastases) indicate its malignant potential. The asymptomatic screen-diagnosed Stage I carcinomas have longer doubling time than the more advanced cancers; nevertheless, they are not overdiagnosed tumors because they cause fatal outcome if they are not resected. Chest X-ray screening identifies approximately 50% of cancers in Stage I. Screening by helical low dose computed tomography scan detects greater than 80% of lung carcinomas in Stage I. The resectability, the surgical techniques (lobectomy vs. limited resections), and the influence of the extent of surgical resection of Stage I NSCLC on prognosis are reviewed. These data show that radical surgical treatment offers 5-year survival rate to 60-80% of patients with Stage I NSCLC. SYNTHESIS. Asymptomatic Stage I lung carcinomas, detected by screening or by incidental findings, are truly malignant, because they metastasize and cause fatal outcome if they are not radically resected. The possibility to cure lung carcinomas relies on radical resection (lobectomy or, less frequently, pneumonectomy) of early diagnosed (Stage I) disease, which is usually asymptomatic. The limited parenchymal resections (segment or wedge resections) do not fulfill the requirements of radicality because they are accompanied by higher incidence of local recurrences and shorter survival rates. CONCLUSIONS. The documented improvement of long term survival of NSCLC, which can be achieved by early diagnosis and radical resection, strongly indicates that the current dogma against lung cancer screening is untrue. Every effort should be made to detect the disease when it is in Stage I and radically operable, by implementing screening in at risk smokers and former smokers, with the most effective screening method that is locally available. Cancer 2000;89:2334-44. (C) 2000 American Cancer Society.
引用
收藏
页码:2334 / 2344
页数:11
相关论文
共 50 条
  • [41] Association Between Cytomorphological and Clinicopathological Features of Nonsmall Cell Lung Carcinoma
    Gulluoglu, Mine G.
    Kilicaslan, Zeki
    Kalayci, Goksel
    Toker, Alper
    Yilazbayhan, Dilek
    [J]. TURKISH THORACIC JOURNAL, 2005, 6 (03): : 181 - 188
  • [42] Natural history of stage I non-small cell lung cancer - Implications for early detection
    Raz, Dan J.
    Zell, Jason A.
    Ou, S-H. Ignatius
    Gandara, David R.
    Anton-Culver, Hoda
    Jablons, David M.
    [J]. CHEST, 2007, 132 (01) : 193 - 199
  • [43] Does screening for stage I lung cancer improve survival in a high-risk population?
    Pastorino, Ugo
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (04): : 218 - 219
  • [44] High-Dose Proton Therapy and Carbon-Ion Therapy for Stage I Nonsmall Cell Lung Cancer
    Iwata, Hiromitsu
    Murakami, Masao
    Demizu, Yusuke
    Miyawaki, Daisuke
    Terashima, Kazuki
    Niwa, Yasue
    Mima, Masayuki
    Akagi, Takashi
    Hishikawa, Yoshio
    Shibamoto, Yuta
    [J]. CANCER, 2010, 116 (10) : 2476 - 2485
  • [45] Treatment of Stage I Lung Cancer Detected by Computed Tomography Screening
    Gierada, David S.
    Bai, Yun Zhu
    Spraker, Matthew B.
    Stilinovic, Anne
    Nava, Ruben G.
    [J]. JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (10):
  • [46] Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer
    He, Jiaxi
    Shen, Jianfei
    Yang, Chenglin
    Jiang, Long
    Liang, Wenhua
    Shi, Xiaoshun
    Xu, Xin
    He, Jianxing
    [J]. MEDICINE, 2015, 94 (22) : e903
  • [47] Definitive chemoradiotherapy in Stage III nonsmall cell lung cancer: Turkey experience
    Yilmaz, Ufuk
    Yilmaz, Ulku
    Yasar, Zehra
    Kirakli, Esra Korkmaz
    Ulger, Sukran
    Ozdogan, Yasemin
    Demirci, Nilgun Yilmaz
    Erol, Serhat
    Ozdogan, Ilker
    Sahin, Burcu
    Koksal, Deniz
    Akcay, Cimen
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 334 - 339
  • [48] Correlation between tumor location and survival in stage I lung adenocarcinoma and squamous cell carcinoma: a SEER-based study
    Hu, Junjie
    Qi, Mengfan
    Zhu, Xinsheng
    Chen, Yan
    Dai, Jie
    Zhang, Jing
    Jiang, Gening
    Zhang, Zhonghong
    Zhang, Peng
    [J]. JOURNAL OF CANCER, 2021, 12 (17): : 5076 - 5085
  • [49] Small-cell carcinoma of the lung detected by CT screening: Stage distribution and curability
    Austin, John H. M.
    Yip, Rowena
    D'Souza, Belinda M.
    Yankelevitz, David F.
    Henschke, Claudia I.
    [J]. LUNG CANCER, 2012, 76 (03) : 339 - 343
  • [50] Lymph node dissection and survival in patients with early stage nonsmall cell lung cancer: A 10-year cohort study
    Shen-Tu, Yang
    Mao, Feng
    Pan, Yan
    Wang, Wenli
    Zhang, Liang
    Zhang, Hui
    Cheng, Baijun
    Guo, Haifa
    Wang, Zhiqiang
    [J]. MEDICINE, 2017, 96 (43)